Prevalence of SARS‐CoV‐2 Antibodies in Kosovo‐Wide Population‐Based Seroepidemiological Study

Author:

Ramadani Naser12,Hoxha‐Gashi Sanije12ORCID,Gexha‐Bunjaku Dafina2,Kalaveshi Arijana12,Jakupi Xhevat12,Humolli Isme3,Vaughan Aisling4,Pebody Richard4,Kacaniku‐Gunga Pranvera2,Jashari Violeta2

Affiliation:

1. Faculty of Medicine University of Pristina “Hasan Pristina” Pristina Kosovo

2. National Institute of Public Health Pristina Kosovo

3. WHO Office in Pristina Pristina Kosovo

4. WHO Regional Office for Europe Copenhagen Denmark

Abstract

ABSTRACTBackgroundSeroprevalence studies have proven to be an important tool in tracking the progression of the coronavirus disease 2019 (COVID‐19) pandemic. The aim of this study was to measure the seroprevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in the general population of Kosovo by gender, age group and region and among asymptomatic people.MethodThe Institute of Public Health of Kosovo conducted a cross‐sectional population‐based survey, aligned with the protocols of the WHO Unity Studies, from the beginning of May to the end of June 2021.ResultsThe survey covered a total of 2204 people with a response rate of 91.8% (41.9% [923] males and 51.2% [1281] females). In May to June 2021, the prevalence of antibodies in the overall population (IgG antibodies ≥ 1.1) was 37.0%. Seroprevalence was 34.4% in men and 38.9% in women (p < 0.05), with the highest percentage (48.7%) found in the 60–69 years' age group. The overall prevalence of acute IgM antibodies (IgM ≥ 1.1) was 1% (95% CI: 0.7%–1.5%), with no significant difference between genders and the highest prevalence among participants of 60–69 years of age (1.6%; 95% CI: 0.7%–3.6%).ConclusionA high prevalence of antibodies against SARS‐CoV‐2 was found in Kosovo before the start of the vaccination campaign. However, the results of the survey suggested that, by the end of June 2021, a desirable level of protection from the SARS‐CoV‐2 virus had not been reached.

Funder

World Health Organization

Publisher

Wiley

Reference32 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. “WHO Statement on Novel Coronavirus in Thailand ” in News release World Health Organization [Website] January 13 2020 (Geneva: World Health Organization 2023) accessed October 18 2023 https://www.who.int/news/item/13‐01‐2020‐who‐statement‐on‐novel‐coronavirus‐in‐thailand.

3. “WHO Director‐General's Opening Remarks at the Media Briefing on COVID‐19 ” World Health Organization [Website] March 11 2020 (Geneva: World Health Organization 2023) accessed October 18 2023 https://www.who.int/director‐general/speeches/detail/who‐director‐general‐s‐opening‐remarks‐at‐the‐media‐briefing‐on‐covid‐19‐‐‐11‐march‐2020.

4. “WHO Coronavirus Disease (COVID‐19) Dashboard [Database]” (Geneva: World Health Organization 2023) accessed October 18 2023 https://covid19.who.int/.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3